Endocrine Abstracts

Introduction: Everolimus is a drug selective inhibitor of mTOR and approved by the FDA in 2011 for treatment of neuroendocrine tumors of pancreatic origin unresectable. Our objective was to evaluate the efficacy and safety of everolimus in a patient with malignant pancreatic head insulinoma.Case: This is a 31 year old man who complains of epigastric pain, dizziness, sweating and syncope related to exercise. During admission is objectively severe hypoglyc...

Introduction and objectives: In clinical practice many professionals are involved in the diabetes treatment. To facilitate this work, we present a computer program, based in recommended guidelines, to improve the management of insulin therapy, called insulinator. We evaluated the correlation between these and clinical practice.Materials and methods: Insulinator has been made so that using a number of variables (weight, HbA1c and glycemic control) offer a...

Objective: To analyze the impact of a specialized management on cardiovascular risk at the onset of type 2 diabetes mellitus.Material and method: Were analyzed 171 patients who visited our diabetes day hospital (DDH) during 2010–2011, studying the following variables: sex, age, BMI, smoking habit, arterial hypertension (de novo/previously known), antihypertensive therapy, dislypidemia (de novo/previously known), hypolipidemic thera...

Objective: To analyze the demographic and clinical characteristics of the patients treated at the onset of type two diabetes mellitus in our DDH.Material and method: During 2010–2011 were analyzed 171 patients treated in our DDH, studying the following variables: sex, age, BMI, waist circumference, family diabetes history, microvascular and macrovascular long-term complications, smoking habit, rate of associated hypertension (de novo/ previ...

Objective: Analyze the use of DPP-4 inhibitors (iDPP4) in a specialized consultation as well as metabolic impact, weight and safety in patients with diabetes mellitus type 2 (DM2).Material and methods: We analyzed 100 patients with DM2, derivative to Diabetes hospital with debut or poor glycemic control. We initiated them sitagliptin 100 mg/day and reinforced Diabetes education. We studied the HbA1c, weight and severe hypoglycemia. Statistical analysis w...